Roche Holding AG (RHHBY)
OTCMKTS: RHHBY · Delayed Price · USD
39.27
-0.05 (-0.13%)
Jul 19, 2024, 3:59 PM EDT - Market closed
Roche Holding AG Employees
Roche Holding AG had 103,605 employees as of December 31, 2023. The number of employees decreased by 8 or -0.01% compared to the previous year.
Employees
103,605
Change (1Y)
-8
Growth (1Y)
-0.01%
Revenue / Employee
$657,295
Profits / Employee
$134,393
Market Cap
253.34B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 103,605 | -8 | -0.01% |
Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
Dec 31, 2021 | 100,920 | -545 | -0.54% |
Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
Dec 31, 2019 | 97,735 | 3,293 | 3.49% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
RHHBY News
- 34 minutes ago - Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs? - Forbes
- 4 days ago - HAYA Therapeutics Appoints Former Roche Global Head of Operations Eric Adam, Ph.D. as Chief Operating Officer - Business Wire
- 4 days ago - New data for Roche's Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions - GlobeNewsWire
- 4 days ago - New Data for Genentech's Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions - Business Wire
- 4 days ago - Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study - Business Wire
- 4 days ago - Roche's Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study - GlobeNewsWire
- 4 days ago - Novo Nordisk, Eli Lilly Slip as Roche Weight-Loss Drug Shows Promise - Investopedia
- 4 days ago - Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk - Market Watch